前列腺癌筛查采用PSA、激肽释放酶组合检测与MRI:ProScreen随机试验
ProScreen试验在芬兰赫尔辛基和坦佩雷随机分配61193名50至63岁无前列腺癌男性,按1:3比例邀请或未邀请接受PSA检测、4-激肽释放酶组合风险评分及MRI筛查。中位随访3.2年,邀请组低级别和高级别前列腺癌累积发病率分别为0.26%和1.13%,未邀请组分别为0.14%和0.62%。
要点
- 邀请组低级别前列腺癌风险差0.11%(95%CI 0.03%-0.20%),高级别风险差0.51%(95%CI 0.33%-0.70%)。
- 每196名受邀男性中额外检出1例高级别前列腺癌,每909名中额外检出1例低级别前列腺癌。
- 作者认为这些初步发现来自单轮筛查,应谨慎解读,有待主要死亡率结局结果。
核心结论
- 在一项正在进行中的随机临床试验的初步描述性报告中,与未受邀筛查者相比,受邀接受单次前列腺癌筛查干预者中每196名男性额外检出1例高级别前列腺癌,每909名男性额外检出1例低级别前列腺癌。
- 这些来自单轮筛查的初步发现应谨慎解读,有待该研究主要死亡率结局的结果。
研究设计与样本
- ProScreen试验是在芬兰赫尔辛基和坦佩雷开展的临床试验,于2018年2月至2020年7月期间按1:3比例随机分配61193名50至63岁无前列腺癌男性接受邀请或不接受邀请进行前列腺癌筛查。
- 最终数据收集截至2023年6月31日。
主要发现
- 60745名合格男性(平均[SD]年龄57.2[4.0]岁)中,15201人被随机分配至受邀组,45544人被随机分配至未受邀组。
- 15201名受邀合格男性中7744人(51%)参与筛查,检出32例低级别前列腺癌(累积发病率0.41%)和128例高级别前列腺癌(累积发病率1.65%),1例癌症分级组结果缺失。
- 7457名(49%)拒绝参与的受邀男性中,检出7例低级别前列腺癌(累积发病率0.1%)和44例高级别前列腺癌(累积发病率0.6%),7例癌症分级组缺失。
- 整个受邀筛查组检出39例低级别前列腺癌(累积发病率0.26%)和172例高级别前列腺癌(累积发病率1.13%)。
- 中位随访3.2年期间,未受邀筛查组检出65例低级别前列腺癌(累积发病率0.14%)和282例高级别前列腺癌(累积发病率0.62%)。
关键数值与推荐
- 参与男性接受PSA检测,PSA水平≥3.0 ng/mL者接受4-激肽释放酶组合风险评分额外检测高级别前列腺癌。
- 激肽释放酶组合评分≥7.5%者接受前列腺MRI,MRI异常者接受靶向活检。
- 整个随机受邀筛查组与对照组相比,低级别前列腺癌风险差为0.11%(95%CI 0.03%-0.20%),高级别前列腺癌风险差为0.51%(95%CI 0.33%-0.70%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些初步发现来自单轮筛查,应谨慎解读,有待该研究主要死亡率结局的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prostate-specific antigen (PSA) screening has potential to reduce prostate cancer mortality but frequently detects prostate cancer that is not clinically important. OBJECTIVE: To describe rates of low-grade (grade group 1) and high-grade (grade groups 2-5) prostate cancer identified among men invited to participate in a prostate cancer screening protocol consisting of a PSA test, a 4-kallikrein panel, and a magnetic resonance imaging (MRI) scan. DESIGN, SETTING, AND PARTICIPANTS: The ProScreen trial is a clinical trial conducted in Helsinki and Tampere, Finland, that randomized 61 193 men aged 50 through 63 years who were free of prostate cancer in a 1:3 ratio to either be invited or not be invited to undergo screening for prostate cancer between February 2018 and July 2020. INTERVENTIONS: Participating men randomized to the intervention underwent PSA testing. Those with a PSA level of 3.0 ng/mL or higher underwent additional testing for high-grade prostate cancer with a 4-kallikrein panel risk score. Those with a kallikrein panel score of 7.5% or higher underwent an MRI of the prostate gland, followed by targeted biopsies for those with abnormal prostate gland MRI findings. Final data collection occurred through June 31, 2023. MAIN OUTCOMES AND MEASURES: In descriptive exploratory analyses, the cumulative incidence of low-grade and high-grade prostate cancer after the first screening round were compared between the group invited to undergo prostate cancer screening and the control group. RESULTS: Of 60 745 eligible men (mean [SD] age, 57.2 [4.0] years), 15 201 were randomized to be invited and 45 544 were randomized not to be invited to undergo prostate cancer screening. Of 15 201 eligible males invited to undergo screening, 7744 (51%) participated. Among them, 32 low-grade prostate cancers (cumulative incidence, 0.41%) and 128 high-grade prostate cancers (cumulative incidence, 1.65%) were detected, with 1 cancer grade group result missing. Among the 7457 invited men (49%) who refused participation, 7 low-grade prostate cancers (cumulative incidence, 0.1%) and 44 high-grade prostate cancers (cumulative incidence, 0.6%) were detected, with 7 cancer grade groups missing. For the entire invited screening group, 39 low-grade prostate cancers (cumulative incidence, 0.26%) and 172 high-grade prostate cancers (cumulative incidence, 1.13%) were detected. During a median follow-up of 3.2 years, in the group not invited to undergo screening, 65 low-grade prostate cancers (cumulative incidence, 0.14%) and 282 high-grade prostate cancers (cumulative incidence, 0.62%) were detected. The risk difference for the entire group randomized to the screening invitation vs the control group was 0.11% (95% CI, 0.03%-0.20%) for low-grade and 0.51% (95% CI, 0.33%-0.70%) for high-grade cancer. CONCLUSIONS AND RELEVANCE: In this preliminary descriptive report from an ongoing randomized clinical trial, 1 additional high-grade cancer per 196 men and 1 low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study's primary mortality outcome. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03423303.
引用
- Auvinen A, Tammela TLJ, Mirtti T, et al. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. JAMA. 2024. PMID: 38581254. doi:10.1001/jama.2024.3841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。